Biogen enhances its portfolio and margins amidst market challenges and competition. Click here to find out why BIIB stock is ...

Fintel reports that on March 25, 2025, Maxim Group downgraded their outlook for CNS Pharmaceuticals (NasdaqCM:CNSP) from Buy ...

Berubicin showed clinically relevant outcomes comparable to Lomustine across multiple endpoints, but not a statistically significant difference in overall survival, the primary endpoint.The safety pro ...

The company also continues development of a ... complete response in a Phase 1 human clinical trial conducted by Reata Pharmaceuticals, Inc. Berubicin was developed by Dr. Waldemar Priebe ...

John "Chip" Scarlett, who as chairman, president and CEO repositioned Geron Corp. and guided the company to its first drug ...

Reata Pharma has reported positive clinical ... in chronic kidney disease and diabetic kidney disease. The big pharma company retained an option to license European rights to bardoxolone in ...

The company is actively searching for a permanent CEO. Bir brings extensive experience in the pharmaceutical industry, having held leadership roles at Reata Pharmaceuticals (NASDAQ:RETA), Inc ...

Existing research indicates that the accuracy of a Parkinson’s disease diagnosis hovers between 55% and 78% in the first five years of assessment. That’s partly because Parkinson’s sibling movement ...